We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04527471
Recruitment Status : Completed
First Posted : August 26, 2020
Results First Posted : September 22, 2022
Last Update Posted : September 22, 2022
Information provided by (Responsible Party):
Verona Pharma plc ( Verona Pharma Inc )

Brief Summary:
This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine delivered via pMDI compared with a matching placebo in conjunction with standard of care treatments on recovery in patients hospitalized due to COVID-19 infection.

Condition or disease Intervention/treatment Phase
Coronavirus Infection Covid-19 SARS-CoV-2 Drug: Ensifentrine Dose 1 Drug: Placebo pMDI Phase 2

Detailed Description:

Expploratory endpoint, pilot study, not statistically powered

go to protocol

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19
Actual Study Start Date : September 4, 2020
Actual Primary Completion Date : February 15, 2021
Actual Study Completion Date : May 1, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Ensifentrine + Standard of Care
30 subjects randomized to receive blinded, inhaled ensifentrine in addition to standard of care treatment for COVID-19 infection
Drug: Ensifentrine Dose 1
Study drug delivered twice daily via pMDI

Placebo Comparator: Placebo + Standard of Care
15 subjects randomized to receive blinded, inhaled placebo in addition to standard of care treatment for COVID-19 infection
Drug: Placebo pMDI
Placebo delivered twice daily via pMDI

Primary Outcome Measures :
  1. Proportion of Patients With Recovery [ Time Frame: Day 29 ]
    Recovery = first day on which subject satisfies one of the following categories: not hospitalized, no limitations of activities; or not hospitalized, limitation of activities, home oxygen requirement, or both.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Capable of giving informed consent indicating that they understand the purpose of the study and study procedures and agree to comply with the requirements and restrictions listed in the informed consent form and in this protocol.
  • Patient must be at least 18 years of age and less than or equal to 80 years of age at the time of informed consent.
  • Males are eligible to participate or females of non-childbearing potential or WOCBP who have a negative pregnancy test at screening are eligible to participate. WOCBP and female partners of male participants agree to either abstinence or use at least one primary form of highly effective contraception not including hormonal contraception from the time of screening through Day 60 following the first dose of study medication.
  • Clinical status consistent with 3, 4 or 5 on the Ordinal scale: Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring any supplemental oxygen; Hospitalized, requiring non-invasive ventilation or use of high flow oxygen devices.
  • Admission to hospital AND have a confirmed diagnosis of severe acute respiratory syndrome coronavirus (SARS-COV-2) infection confirmed by polymerase chain reaction (PCR) test AND displays at least one of the following: Respiratory rate > 24 breaths per minute; new cough; new atypical chest pain; new dyspnea; oxygen saturation < 97% at rest; chest x-ray with new changes consistent with COVID-related airspace disease.
  • Capable of complying with all study restrictions and procedures including ability to use the pMDI correctly.

Exclusion Criteria:

  • Participation in any other clinical trial of an experimental treatment for COVID-19, unless related to an expanded access program as part of Standard of Care at screening or during study.
  • Evidence of multiorgan failure.
  • Requiring mechanical ventilation at screening.
  • Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN) at screening.
  • Creatinine clearance < 30 mL/min at screening.
  • Pregnancy or lactation at screening.
  • Allergy or other contraindication or one of ensifentrine.
  • In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
  • Use of prohibited medications (theophylline, PDE4 inhibitors [e.g. roflumilast, apremilast, crisaborole] within 48 hours of screening or during study)
  • Any other reason that the Investigator considers makes the patient unsuitable to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04527471

Layout table for location information
United States, Alabama
The University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
Verona Pharma Inc
  Study Documents (Full-Text)

Documents provided by Verona Pharma plc ( Verona Pharma Inc ):
Study Protocol  [PDF] October 13, 2020
Statistical Analysis Plan  [PDF] March 17, 2021

Layout table for additonal information
Responsible Party: Verona Pharma Inc
ClinicalTrials.gov Identifier: NCT04527471    
Other Study ID Numbers: RPL554-COV-201
First Posted: August 26, 2020    Key Record Dates
Results First Posted: September 22, 2022
Last Update Posted: September 22, 2022
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Verona Pharma will not be sharing individual deidentified participant data or other relevant study documents.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Pneumonia, Viral
Respiratory Tract Infections
Virus Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases